Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.
https://defensescoop.com/2023/09/21/army-awards-microsoft-95m-for-additional-ivas-1-2-headsets-virtual-trainers/The Army is gearing up for expanded testing of the latest variant of Microsoft's Integrated Visual